Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis

By sjmartinez • January 8, 2024

Kingston P, Blauvelt A, Strober B, Armstrong AW. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. J Psoriasis Psoriatic Arthritis. 2023 Oct;8(4):156-165. doi: 10.1177/24755303231201336. Epub 2023 Sep 5. PMID: 38188537; PMCID: PMC10768812.

Tags: Dermatology, deucravacitinib, efficacy, mechanism of action, psoriasis, Publications, review, safety, TYK2, tyrosine kinase

Contact Dermatitis in the United States: A Population-Based Study on Patient Visit Characteristics and Treatment Prescription Patterns

Hao A, Yu RP, Kikuchi R, Sadrolashrafi K, Guo L, Yamamoto RK, Tolson H, Yee D, Bilimoria S, Pourali SP, Adler BL, Armstrong AW. Contact[...]

Radiation therapy for a case of poikilodermatous plaques in an otherwise healthy young man: A case report

Biba U, Poppens MJ, Collier EK, Cheng K. Radiation therapy for a case of poikilodermatous plaques in an otherwise healthy young man: A case report.[...]

Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer

Chow F, Lamoureux F, Moriceau G. Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer. Front Immunol. 2024 Sep 26;15:1487952. doi: 10.3389/fimmu.2024.1487952. PMID: 39391312; PMCID: PMC11464455.